Advertisement
UK markets close in 3 hours 45 minutes

  • FTSE 100

    8,086.59
    +41.78 (+0.52%)
     

  • FTSE 250

    19,802.64
    +2.92 (+0.01%)
     

  • AIM

    754.77
    -0.10 (-0.01%)
     

  • GBP/EUR

    1.1637
    +0.0009 (+0.08%)
     

  • GBP/USD

    1.2435
    -0.0017 (-0.14%)
     

  • Bitcoin GBP

    53,520.41
    +501.73 (+0.95%)
     

  • CMC Crypto 200

    1,438.08
    +13.98 (+0.98%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    82.88
    -0.48 (-0.58%)
     

  • GOLD FUTURES

    2,328.20
    -13.90 (-0.59%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,188.05
    +50.40 (+0.28%)
     

  • CAC 40

    8,136.83
    +31.05 (+0.38%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Nexstim Receives an NBT® System Order from a New Therapy Customer in Finland

Nexstim Oyj
·2-min read

Press Release, Helsinki, 29 April 2021 at 10:00 AM (EEST)

Nexstim Receives an NBT® System Order from a New Therapy Customer in Finland

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received a new NBT® System order from a therapy customer in Finland.

This is a new customer for Nexstim and the system will be used to treat Major Depressive Disorder (MDD).

Nexstim’s NBT® System with SmartFocus® nTMS is highly differentiated from other currently available TMS products due to its unique and highly sophisticated 3D navigation that uses its proprietary E-field algorithm to visualize the exact location, orientation, and magnitude of the stimulation.

ADVERTISEMENT

Mikko Karvinen, CEO of Nexstim says: "Glad to announce the sale of this NBT® system and to welcome our new therapy customer. We are happy to see growing interest to our therapy systems also in Finland.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Attachment